Mitaclau (Desmopressin)

Desmopressin mimics the natural hormone vasopressin. It binds to V2 receptors in the renal collecting ducts, increasing cyclic AMP and inserting aquaporin‑2 channels, which allows the kidneys to reabsorb more water. It also stimulates V1 receptors on endothelial cells, causing release of factor VIII and von Willebrand factor, aiding haemostasis.

The appropriate dose of Mitaclau is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and response to therapy. No fixed regimen is provided here; the prescriber will set the dosage and schedule according to clinical guidelines.

Safety data for desmopressin in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against risks and discuss use with a qualified obstetric or pediatric specialist before prescribing to pregnant or nursing individuals.

To request Mitaclau, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with traditional vasopressin, desmopressin (Mitaclau) has a longer half‑life, greater selectivity for V2 receptors and minimal V1‑mediated vasoconstrictive effects. This results in more predictable antidiuretic action and a lower risk of blood pressure elevation, making it a preferred option for chronic management of water‑balance disorders.

Mitaclau should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mitaclau is taken sublingually. The tablet is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Patients should follow the prescriber’s instructions regarding timing relative to meals and fluid intake to optimise absorption.

The most critical safety concerns are severe hyponatremia, water intoxication and thromboembolic events. These can lead to seizures, coma, cerebral edema or clot formation. Prompt monitoring of serum sodium and fluid balance is essential, especially in patients with renal impairment or those taking interacting medications.

Mitaclau is contraindicated in individuals with known hypersensitivity to desmopressin or any excipients, in patients with uncontrolled hypertension, and in those with severe renal impairment where fluid balance cannot be safely managed. Clinicians should also avoid use in patients at high risk for hyponatremia without close monitoring.